Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5–6 in non-addicted infants by Zimmermann-Baer, U et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Finnegan neonatal abstinence scoring system:
normal values for first 3 days and weeks 5-6 in
non-addicted infants
Zimmermann-Baer, U; Nötzli, U; Rentsch, K; Bucher, H U
Zimmermann-Baer, U; Nötzli, U; Rentsch, K; Bucher, H U (2010). Finnegan neonatal abstinence scoring system:
normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction, 105(3):524-528.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Addiction 2010, 105(3):524-528.
Zimmermann-Baer, U; Nötzli, U; Rentsch, K; Bucher, H U (2010). Finnegan neonatal abstinence scoring system:
normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction, 105(3):524-528.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Addiction 2010, 105(3):524-528.
 1  
Finnegan neonatal abstinence scoring system: 
normal values for first 3 days and week 5 to 6 
in non-addicted infants 
 
 
Urs Zimmermann-Baer*#, Ursula Nötzli*, Katharina Rentsch°, Hans Ulrich Bucher* 
 
*Division of Neonatology, Department of Obstetrics and Gynecology, University 
Hospital Zurich, Switzerland;  
#Division of Neonatology, Department of Pediatrics, Children’s Hospital, 
Kantonsspital Winterthur, Switzerland  
°Institute for Clinical Chemistry, University Hospital Zurich, Switzerland 
 
 
Address for Correspondence 
Bucher Hans Ulrich, MD 
Division of Neonatology 
University Hospital  
CH – 8091 ZURICH 
SWITZERLAND 
Phone: 0041 44 255 53 41 
Fax: 0041 44 255 44 42 
Email: buh@usz.ch 
 
 
Conflict of interest 
All authors have no conflict of interest relevant to this article to disclose 
 
 
 
 2  
Abstract 
 
OBJECTIVE. The neonatal abstinence scoring system proposed by Finnegan is used 
widely in neonatal units to initiate and to guide therapy in babies of opiate dependent 
mothers. The purpose of this study was to assess the variability of the scores in 
newborns and infants not exposed to opiates during the first three days of life and 
during 3 consecutive days in week 5 or 6. 
PATIENTS AND METHODS. Healthy neonates born after 34 completed weeks of 
gestation whose parents denied opiate consumption and gave informed consent 
were included in this observational study. Infants with signs or symptoms of disease 
or with feeding problems were excluded. A modified scoring system was used every 
8 hours during 72 hours by trained nurses. 102 neonates were observed for the first 
3 days of life and 26 neonates in week 5 to 6. A meconium sample and a urine 
sample at week 5 to 6 were stored from all infants to be analysed for drugs when the 
baby scored high. Given a non-Gaussian distribution the scores were represented as 
percentiles. 
RESULTS. During the first three days of life median scores remained stable at 2, but 
the variability increased, with the 95th percentile rising from 5.5 on day 1 to 7 on day 2. 
At week 5 to 6 median values were higher during day time (50th percentile = 5, 95th 
percentile = 8) than night time (50th percentile = 2, 95th percentile = 6, p=0.02).  
CONCLUSION. Scores increase from day 1 - 3 to week 5 - 6 and show day-night-
cycles with 5 to 6 weeks. Values above 8 can be considered pathological. This data 
may help to raise suspicion of narcotic withdrawal and to guide therapy. 
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Introduction 
Withdrawal symptoms in an infant born to a mother addicted to heroin were first 
described 50 years ago.1 In 1975 Loretta Finnegan published a scoring system for 
the neonatal abstinence syndrome she had devised as both a clinical and 
investigative tool.2 This score lists all relevant clinical signs of withdrawal in newborn 
infants during the first days of life comprehensively, and assesses central nervous 
system hyperirritability, gastrointestinal dysfunction, respiratory distress and vague 
autonomic signs in a semi-quantitative way. Unfortunately these signs lack specificity.   
Originally Finnegan suggested that the score should be further improved in order to 
avoid “ambiguous and redundant items which may contribute to the error variance”2. 
As a consequence a variety of modified Finnegan scores, as they were called, have 
been widely used to guide and compare various therapies of the neonatal abstinence 
syndrome.3 As substance abuse during pregnancy is still a common problem in many 
countries, the Finnegan score is still useful today.4  
Compared with the original version, the following modifications of the Finnegan score 
are usually applied:5  “Hyperactive Moro reaction” was dropped since it is a sign of 
central nervous system hyperirritability and therefore redundant to “tremors”. 
“Moyoclonic jerks” shown to be highly specific for opiate withdrawal were added 
instead.6 Excoriations on nose, knees or toes were changed to “excoriation of the 
skin” and only one point was given instead of one for each area. Excoriations of the 
skin are due to vigorous movements and thus also consequences of central nervous 
system hyperirritability. Since newborns are, in contrast to the 1970s, put to sleep on 
their back, these excoriations are no longer seen on nose or knees.  
In clinical practice scores above 8 are considered high and suggestive of neonatal 
withdrawal. Pharmacological treatment of withdrawal is started if the modified 
Finnegan score is above 9 on at least two occasions. Originally the scoring was 
applied every 4 hours, which may be appropriate for scientific purposes. For clinical 
use scoring every 8 hours, i.e. once per shift, proved to be adequate.      
 
  
 
Although the score is widely used there are only few studies that assess its reliability 
and validity. We therefore applied the score to a cohort of non-addicted neonates and 
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infants to define its variability in the absence of drug withdrawal, its day-night cycles 
and its course with age. 
 
Methods 
102 healthy neonates born after 34 completed weeks of gestation whose parents 
denied opiate consumption and gave informed consent were included in this 
observational study. Exclusion criteria were malformations, birth trauma, and infants 
at increased risk for group B streptococcus infection (mother carrier without 
appropriate antibiotic prophylaxis). 
Each infant was examined and history about alcohol, nicotine or drug use during 
pregnancy was taken from the mother. A meconium sample was collected and stored 
in a deep freezer. These samples were later analysed for substances in all cases in 
whom Finnegan score exceeded the 95th percentile once or the 90th percentile twice 
during the observation period to exclude drug exposure during pregnancy. Meconium 
analysis offers an accurate method of quantifying the level of drug misuse in 
pregnancy as shown in several large studies.7-9 The meconium samples were 
analysed by a validated procedure which consisted of the extraction of the drugs 
abused by the mother into organic solvents and thereafter an immunological drug 
screening test (Roche, Basel, Switzerland). Positive results were confirmed with high 
pressure liquid chromatography (HPLC) (Remedi, BioRad, Riehen, Switzerland). 
The infants were observed in the maternity ward by trained nurses. Episodes of 
sleeping, crying and feeding were noted for the first 72 hours. A modified Finnegan 
score ranging from 0 to 37 was applied every 8 hours (Table 1).  
26 infants of the original cohort were observed again at week 5 or 6 of life for 72 
consecutive hours. Infants who had feeding problems, had been vaccinated during 
the last two days, showed any signs or symptoms of disease or whose parents were 
unlikely to comply were excluded. The same nurses who had observed the infants 
during the first three days assessed the infants at home at 8 am, at 4 pm and at 
midnight for three consecutive days assisted by the mothers who had been instructed 
to monitor their infants during their first three days at hospital. The same observation 
form with 8 hour assessments of the modified Finnegan score was used as for the 
first 3 days. A urine sample was deep frozen for investigation of drugs if scores were 
once above the 95th percentile or twice above the 90th percentile. Urine samples were 
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analysed using commercial automated drugs-of-abuse immunoassays on the Integra 
instrument (Roche, Basel, Switzerland). 
The study protocol was approved by the local ethics committee and all parents gave 
informed consent. 
The results were plotted with percentiles given a non-Gaussian distribution of the 
scores. The upper limit of the normal range was defined at the 95th percentile. Mann 
Whitney U test was used to compare two groups with significance level at 0.05. 
 
Results 
The characteristics of the infants included in cohort 1 (first 72 hours) and cohort 2 
(week 5 or 6) are given in table 2. The two cohorts did not differ significantly in any 
aspect. 15 (4) mothers reported smoking 1 to 10 cigarettes per day and 5 (1) mother 
reported sporadic alcohol intake never exceeding 2 glasses of wine during pregnancy. 
All mothers denied illicit drug consumption.  
In cohort 1 median scores remained stable during the first three days of life at 2, but 
the variability increased, P95 raising from 5.5 on day 1 to 7 on day 2 (figure 1). Five 
infants had scores between 8 and 11 at one assessment but dropped below 8 at the 
next assessment. Meconium analysis done in these infants did not reveal opiates, 
methadone, cocaine, benzodiazepines, barbiturates or amphetamines. 
There was no statistically significant difference between girls and boys and between 
day and night. Infants delivered by Ventouse or whose mothers had smoked during 
pregnancy did not show higher scores than the others. A detailed analysis of the 
singular components showed that high pitched cry, short sleep after feeding, vomiting 
and sneezing were frequent during the whole observation period (figure 2).   
At week 5 to 6 median values were significantly higher during day time (50th 
percentile=5, 95th percentile=8) than during night time (50th percentile=2, 95th 
percentile=6; p=0.02) (figure 3). Sleep duration after feeding and sneezing 
contributed most to the circadian cycles (figure 4). Urine samples of six infants with 
high scores were analysed for opiates, methadone, amphetamines, cocaine, 
barbiturates and benzodiazepines. None of those substances were detected. 
  
Discussion 
We report the distribution of the Finnegan score in infants not exposed to drugs in 
utero. These findings are important for the interpretation of the score in neonatal 
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abstinence syndrome, giving a baseline for healthy infants against which withdrawal 
symptoms can be compared. As the 95th percentile never exceeds 8, this cut-off may 
be reasonable to raise suspicion for drug withdrawal and to initiate pharmacological 
treatment in infants of substance abusing mothers. 
We were not able to find a similar study with an extended literature search in 
MEDLINE and EMBASE. Two important features of the score have to be pointed out: 
1) The score increases with age. This phenomenon is related to brain maturation and 
reflects well known developmental changes in behaviour, especially in crying 
patterns.10  2) A circadian rhythm is established by week 5 or 6. This fact also reflects 
developmental maturation.11 It is noteworthy that this variation is mainly due to longer 
duration of night sleep.  
The original score suggested by Finnegan was modified, as described in the 
introduction.  As the modified items occurred very rarely in our cohort, the results are 
hardly affected by these modifications.   
The strengths of this study are the selection of patients with exclusion of drug 
ingestion by meconium analysis in subjects with high scores, the inclusion of patients 
after Ventouse delivery and nicotine exposure before birth, the use of an observation 
scheme identical to that used in narcotic abstinence syndrome by nurses who have 
experience with scoring infants with withdrawal symptoms.  
The weaknesses are that the score was applied by various nurses and in part by the 
parents for week 5 or 6, which may increase variability. A video recording which 
would allow post-hoc analysis would be more objective but need much more time 
without improving variability.  
Up to 5% of infants born to mothers not reporting drug use may have been exposed 
to opiates in utero.8, 12 We examined meconium or urine samples only in infants with 
high scores in order to ensure that these elevated scores were not due to an 
unknown opiate abstinence syndrome. Our methodology does not exclude that an 
infant with permanent low scores was exposed to opiates in utero. This limitation 
does not affect our results, at least not the 95th percentile, because any infant with 
significant signs of opiate withdrawal should have been detected.   
 
 
Monitoring the abuse of drugs during pregnancy is a difficult task, as mothers may 
take these drugs intermittently and urine tests therefore may be negative. Instead, 
 7  
the analysis of meconium samples, which act as garbage accumulation bin during the 
last 5 months of pregnancy, is the contemporary approach for detecting drug 
exposure in neonates. As no standardised procedure for the extraction and analysis 
of meconium samples has been published to date, each laboratory has to develop 
and validate its own procedure. This leads to different results of meconium drug 
screening tests in different laboratories. Therefore, clinical methods are 
indispensable for the identification of infants suspected to narcotic withdrawal.13 
 
Conclusions 
From this study there are two implications for the use of the Finnegan score: In 
infants who score higher than 8, narcotic withdrawal should be suspected. If the 
score is used to guide therapy for abstinence syndrome, an increase of the baseline 
and day-night-cycles present at 5 to 6 weeks have to be taken into account.  
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Tables 
 
Table 1. Modified Finnegan score  
CNS Symptoms   
High pitched cry 2 
High pitched cry > 2 h 3 
Sleeps less than 3 h after feeding 1 
Sleeps less than 2 h after feeding 2 
Sleeps less than 1 h after feeding 3 
Mild tremors when disturbed 1 
Marked tremors when disturbed 2 
Mild tremors when undisturbed 3 
Marked tremors when undisturbed 4 
Increased muscle tone 2 
Excoriation of skin 1 
Myoclonic jerks in sleep 3 
Generalized convulsions 5 
Vegetative Symptoms   
Sweating 1 
Temperature 37.5 – 38.0 °C 1 
Temperature  > 38.0 °C 2 
Frequent yawning 1 
Mottling 1 
Nasal stuffiness 1 
Sneezing 1 
Gastrointestinal Symptoms    
Frantic sucking 1 
Poor feeding 2 
Regurgitation 2 
Projectile vomiting 3 
Loose stools 2 
Watery stools 3 
Respiratory Symptoms   
Tachypnea >60/min 1 
Tachypnea >60/min with retractions 2 
Total Score (minimum 0, maximum 35)   
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Table 2. Patient characteristics  
  Cohort 1 (first 72 hours) Cohort 2 (week 5 or 6) 
N 102 26 
Gestational age (median, range) 39 4/7 [36 5/7 - 41 5/7] 39 4/7 [36 6/7 - 41 5/7] 
Birth weight (median, range) 3255 [2380 - 4620] g 3250 [2380 - 4620] g 
Girls (n,%) 42 (42%) 11 (42%) 
Smoking in pregnancy (n,%) 15 (15%) 4 (15%) 
Apgar scores  at 5 min (median, 
range) 9 (8 - 10) 9 (8 - 10) 
Umbilical artery pH (median, range) 7.26 (7.02 - 7.42) 7.26 (7.02 - 7.42) 
Spontaneous vaginal delivery 65 (63%) 18 (69%) 
Cesarean section (n, %) 31 (31%) 6 (22%) 
Delivery by ventouse (n,%) 6 (6%) 2 (7%) 
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Fig. 1.  Score during the first 72 hours of life (n=102) 
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Fig. 2.  Single components of the score during the first 72 hours of life. Excoriation of 
skin, myoxlonic jerks in sleep, sweating, frequent yawning, mottling and tachypnea 
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were rarely observed and are summarised as “various”. Generalized convulsions 
never occurred. 
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Fig. 3.  Score at week 5 to 6 (n=26) 
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Fig. 4.  Single components of the score at week 5 and 6. “Various” includes tremor, 
excoriation of the skin, myoclonic jerks in sleep, fever and tachypnea. 
